An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications

doi:10.5662/wjm.v3.i4.45

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9263)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

541

WORD

338

HTML

7658

Figures (1-9)

449

Tables (1-2)

277

Sum=9263

Dec 26, 2013 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Dec 26, 2013; 3(4): 45-64
Published online Dec 26, 2013. doi: 10.5662/wjm.v3.i4.45

Table 2 Dosimetry aspects of different anticancer therapeutic agents under pre-clinical and clinical investigation

Therapeutics	Dosimetry calculations	Species	Targeting tissue	Pathology	Dose to tumor(mGy/MBq)	Ref.
¹³¹I-Hyp	OLINDA/EXM software	RPLI rats	Necrotic tissue	Solid tumors	276–93600	[79]
¹³¹I-Labeled TNT-1 monoclonal antibody	Organ uptake-time integration by trapezoid method Whole body image analysis	Nude mice bearing ME-180 human cervical tumors	Histone fraction H1 in necrotic tissues	Cervical carcinoma cell	366–3610	[31]
¹³¹I-m-iodobenzylguanidine (MIBG)	MicroPET/CT 124I-MIBG OLINDA/EXM software	Mice bearing A431 human epithelial carcinoma xenografts	Norepinephrine transporter	Neuroblastoma	97–380	[80]
¹³¹I- labeled monoclonal antibody MN-14	MIRDOSE3 software	Nude mice with intraperitoneal LS174T tumors	Carcinoembryonic antigen	Peritoneal metastases of colorectal origin	-16200	[89]
¹³¹I-tositumomab	SPECT/CT Imaging DPM Monte Carlo electron and photon transport program	Humans	CD20-positive B-cells	Refractory B-cell NHL	2.81 (mean)	[81]
¹⁷⁷Lu-DOTA-AE105	Organ uptake-time integration by trapezoid method Sphere model	Nude mice bearing colorectal HT-29 tumor	uPAR-positive HT-29 xenograft	Colorectal cancer	5.8	[82]
¹⁷⁷Lu-pertuzumab	Organ uptake-time integration by trapezoid method Sphere model	BALB/c (nu/nu) Mice with HER-2–overexpressing xenografts	HER-2 tyrosine kinase receptor	Breast cancer	-6900	[83]
¹⁸⁶Re-1-hydroxy- ethylidene-1,1 diphosphonic acid	MIRDOSE 3.1 software	Humans	Bone mineral metabolite	Skeletal metastases	23–34	[84]
⁹⁰Y-ibritumomab tiuxetan	PET/CT Imaging DPM ⁸⁹Zr-ibritumomab tiuxetan OLINDA/EXM software	Humans	CD20-positive B-cells	Relapsing NHL	8.6–28.6	[85]
⁹⁰Y- DOTA0-DPhe1-Tyr3- octreotide	SPECT/CT Imaging DPM 111In-DOTA-TOC	Humans	Somatostatin receptor subtype 2	NETs	4-31 (mean 10)	[86]

CT: Computed tomography; DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid;

¹³¹I: Iodine-131;

¹⁷⁷Lu: Lutetium-177; NETs: Neuroendocrine tumors; OLINDA/EXM: Organ level internal dose assessment/exponential modeling; PET: Positron emission tomography;

¹⁸⁶Re: Rhenium-186; RPLI: Reperfused partial liver infarction; SPECT: Single-photon emission computed tomography; TNT: Tumor necrosis treatment; DPM: Dose planning method; NHL: Non-Hodgkin lymphoma; DOTA-TOC:

⁹⁰Y- DOTA0-DPhe1-Tyr3-octreotide; ⁹⁰Y: Yttrium-90.

Citation: Cona MM, Witte P, Verbruggen A, Ni Y. An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications. World J Methodol 2013; 3(4): 45-64
URL: https://www.wjgnet.com/2222-0682/full/v3/i4/45.htm
DOI: https://dx.doi.org/10.5662/wjm.v3.i4.45